Klotho in kidney diseases : a crosstalk between the renin-angiotensin system and endoplasmic reticulum stress
© The Author(s) 2021. Published by Oxford University Press on behalf of the ERA..
Klotho is a transmembrane anti-ageing protein that exists in three forms, i.e. α-Klotho, β-Klotho and γ-Klotho, with distinct organ-specific expression and functions in the body. Here we focus on α-Klotho (hereafter Klotho), abundantly expressed by the distal and proximal convoluted tubules of the kidney. A significant decline in systemic and renal Klotho levels is a new hallmark for kidney disease progression. Emerging research portrays Klotho as a promising diagnostic and therapeutic target for diabetic and non-diabetic kidney disease. Even so, the underlying mechanisms of Klotho regulation and the strategies to restore its systemic and renal levels are still lacking. Angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers are the current standard of care for kidney diseases, but the molecular mechanisms for their nephroprotective action are still ambiguous. Moreover, endoplasmic reticulum (ER) stress also plays a crucial role in kidney disease progression. Few studies have claimed that the renin-angiotensin-aldosterone system (RAAS) has a direct relation with ER stress generation and vice versa in kidney disease. Interestingly, RAAS and ER stress modulation are associated with Klotho regulation in kidney disease. Here we focus on how the RAAS and ER stress connect with Klotho regulation in kidney disease. We also discuss Klotho and ER stress in an alliance with the concept of haemodynamic and metabolic overload in kidney disease. In addition, we highlight novel approaches to implement Klotho as a therapeutic target via RAAS and ER stress modulation for the treatment of diabetic and non-diabetic kidney diseases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association - 38(2023), 4 vom: 31. März, Seite 819-825 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kale, Ajinath [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 04.04.2023 Date Revised 12.04.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/ndt/gfab340 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM333870328 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM333870328 | ||
| 003 | DE-627 | ||
| 005 | 20231225222532.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ndt/gfab340 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1112.xml |
| 035 | |a (DE-627)NLM333870328 | ||
| 035 | |a (NLM)34850136 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kale, Ajinath |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Klotho in kidney diseases |b a crosstalk between the renin-angiotensin system and endoplasmic reticulum stress |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.04.2023 | ||
| 500 | |a Date Revised 12.04.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2021. Published by Oxford University Press on behalf of the ERA. | ||
| 520 | |a Klotho is a transmembrane anti-ageing protein that exists in three forms, i.e. α-Klotho, β-Klotho and γ-Klotho, with distinct organ-specific expression and functions in the body. Here we focus on α-Klotho (hereafter Klotho), abundantly expressed by the distal and proximal convoluted tubules of the kidney. A significant decline in systemic and renal Klotho levels is a new hallmark for kidney disease progression. Emerging research portrays Klotho as a promising diagnostic and therapeutic target for diabetic and non-diabetic kidney disease. Even so, the underlying mechanisms of Klotho regulation and the strategies to restore its systemic and renal levels are still lacking. Angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers are the current standard of care for kidney diseases, but the molecular mechanisms for their nephroprotective action are still ambiguous. Moreover, endoplasmic reticulum (ER) stress also plays a crucial role in kidney disease progression. Few studies have claimed that the renin-angiotensin-aldosterone system (RAAS) has a direct relation with ER stress generation and vice versa in kidney disease. Interestingly, RAAS and ER stress modulation are associated with Klotho regulation in kidney disease. Here we focus on how the RAAS and ER stress connect with Klotho regulation in kidney disease. We also discuss Klotho and ER stress in an alliance with the concept of haemodynamic and metabolic overload in kidney disease. In addition, we highlight novel approaches to implement Klotho as a therapeutic target via RAAS and ER stress modulation for the treatment of diabetic and non-diabetic kidney diseases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a ER stress | |
| 650 | 4 | |a Klotho | |
| 650 | 4 | |a haemodynamic and metabolic overload | |
| 650 | 4 | |a kidney disease | |
| 650 | 4 | |a renin–angiotensin system | |
| 650 | 7 | |a Angiotensin-Converting Enzyme Inhibitors |2 NLM | |
| 650 | 7 | |a Klotho Proteins |2 NLM | |
| 650 | 7 | |a EC 3.2.1.31 |2 NLM | |
| 700 | 1 | |a Sankrityayan, Himanshu |e verfasserin |4 aut | |
| 700 | 1 | |a Anders, Hans-Joachim |e verfasserin |4 aut | |
| 700 | 1 | |a Gaikwad, Anil Bhanudas |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association |d 1990 |g 38(2023), 4 vom: 31. März, Seite 819-825 |w (DE-627)NLM012639206 |x 1460-2385 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2023 |g number:4 |g day:31 |g month:03 |g pages:819-825 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ndt/gfab340 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2023 |e 4 |b 31 |c 03 |h 819-825 | ||